1. Home
  2. CTM vs GANX Comparison

CTM vs GANX Comparison

Compare CTM & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CTM

Castellum Inc.

HOLD

Current Price

$0.72

Market Cap

93.7M

Sector

Technology

ML Signal

HOLD

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$2.13

Market Cap

78.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTM
GANX
Founded
2019
2017
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
93.7M
78.2M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
CTM
GANX
Price
$0.72
$2.13
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$3.00
$7.50
AVG Volume (30 Days)
1.2M
548.9K
Earning Date
05-08-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
83.33
31.46
EPS
N/A
N/A
Revenue
$52,866,001.00
$55,180.00
Revenue This Year
$20.36
N/A
Revenue Next Year
$6.37
N/A
P/E Ratio
N/A
N/A
Revenue Growth
18.10
N/A
52 Week Low
$0.48
$1.41
52 Week High
$1.56
$4.34

Technical Indicators

Market Signals
Indicator
CTM
GANX
Relative Strength Index (RSI) 50.15 53.96
Support Level $0.48 $1.55
Resistance Level $1.21 $2.40
Average True Range (ATR) 0.06 0.14
MACD 0.02 0.05
Stochastic Oscillator 86.77 84.46

Price Performance

Historical Comparison
CTM
GANX

About CTM Castellum Inc.

Castellum Inc is engaged in providing information technology services. The company provides financial services, healthcare, and other users of large data applications with services that include intelligence analysis, software development, software engineering, program management, strategic and mission planning, information assurance, cybersecurity and policy support, data analytics, and MBSE. In addition to constantly innovating and enhancing organic capabilities, Castellum is acquiring technology companies in the areas of cybersecurity, information technology, electronic warfare, information warfare, and information operations with businesses in the defense, federal, civilian, and commercial markets.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.

Share on Social Networks: